SCHEMBL1287944

SCHEMBL1287944

C[C@H](O)[C@H](CO)NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 6/20 0.54
CA2 P00918 5/20 0.54
CA12 O43570 3/20 0.54
CA9 Q16790 3/20 0.54
CA14 Q9ULX7 3/20 0.54
CA1 P00915 4/20 0.50
MMP1 P03956 3/20 0.50
MMP9 P14780 3/20 0.50
MMP13 P45452 3/20 0.50
MMP8 P22894 3/20 0.50
MMP3 P08254 2/20 0.50
MMP7 P09237 2/20 0.50
MMP14 P50281 1/20 0.49
CA3 P07451 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA7 P43166 1/20 0.47
CA13 Q8N1Q1 1/20 0.47
CA5B Q9Y2D0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1288009 1.00 MMP2 (0.54) MMP2CA2CA12CA9CA14
SCHEMBL1287919 1.00 MMP2 (0.54) MMP2CA2CA12CA9CA14
SCHEMBL3177089 0.89 MMP2 (0.55) MMP2CA2CA12CA9CA14
SCHEMBL3177364 0.86 MMP2 (0.52) MMP2CA2CA12CA9CA14
SCHEMBL3177370 0.86 MMP2 (0.52) MMP2CA2CA12CA9CA14
SCHEMBL3198456 0.85 CA2 (0.56) MMP2CA2CA12CA9CA14
SCHEMBL13335267 0.85 CA2 (0.56) MMP2CA2CA12CA9CA14
SCHEMBL3177359 0.85 CA2 (0.56) MMP2CA2CA12CA9CA14
SCHEMBL1716737 0.83 MMP2 (0.49) MMP2CA2CA12CA9CA14
SCHEMBL1716735 0.83 MMP2 (0.49) MMP2CA2CA12CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310384-A1 Sulfonamide-Containing Compounds THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2013-11-21 US disclosed
WO-2012047926-A2 SULFONAMIDE-CONTAINING COMPOUNDS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310384-A1 Sulfonamide-Containing Compounds BACE1, BACE2, GSAP MMP2 3089/4885CA2 833/4885CA12 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.